Notice: Images are for illustration only and may not reflect the exact product you receive. Brand-name medications may look different depending on their country of origin—Canadian versions, for example, often include a "PR" symbol on the packaging. Rest assured, the medication, dosage, and active ingredients will be exactly as prescribed. Canada Pharmacy Store is committed to your health and safety, and we work only with licensed pharmacies to ensure you receive trusted, high-quality medication every time.
General Medication Fact Sheet for Tecentriq
| Field | Information |
|---|---|
| Medication Name | Tecentriq |
| Generic Name | Atezolizumab |
| Boxed/Label Warning | Immune-Mediated Adverse Reactions (serious and sometimes fatal) |
| Purpose | Immunotherapy used to treat various types of cancer, including lung cancer, bladder cancer, and breast cancer. |
| Mechanism of Action | Atezolizumab is a programmed death-ligand 1 (PD-L1) blocking antibody. It binds to PD-L1 and blocks its interaction with PD-1 and B7.1 receptors, releasing PD-1 pathway-mediated inhibition of the immune response. |
| Dosage Forms | Intravenous (IV) infusion |
| Available Strengths | 840 mg/14 mL (56 mg/mL), 1200 mg/20 mL (60 mg/mL) |
| Dosage Frequency | Varies depending on the type of cancer and treatment regimen; typically administered every 2, 3, or 4 weeks. |
| Common Side Effects | Fatigue, decreased appetite, nausea, cough, dyspnea (shortness of breath), musculoskeletal pain |
| Serious Side Effects | Immune-mediated adverse reactions (pneumonitis, hepatitis, colitis, endocrinopathies, nephritis), infusion-related reactions. |
| Drug Interactions | Corticosteroids or other immunosuppressants may diminish the efficacy of Tecentriq. Avoid use prior to stem cell transplantation. |
| Important Notes | Patients should be monitored for immune-mediated adverse reactions during treatment and after discontinuation of Tecentriq. |
| Storage | Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze. |
| Missed Dose | Contact your healthcare provider immediately to reschedule your appointment. Do not attempt to make up the missed dose on your own. |
| Alternatives | Keytruda (pembrolizumab), Opdivo (nivolumab), Yervoy (ipilimumab) |
Tecentriq Alternatives
| Medication | Mechanism of Action | Notes |
|---|---|---|
| Keytruda (pembrolizumab) | PD-1 inhibitor | Another immunotherapy drug used to treat various cancers. |
| Opdivo (nivolumab) | PD-1 inhibitor | An immunotherapy option that may be used for similar types of cancer as Tecentriq. |
| Yervoy (ipilimumab) | CTLA-4 inhibitor | Immunotherapy that may be used in combination with other agents. |
Tecentriq Side Effects
| Common Side Effects | Serious Side Effects |
|---|---|
| Fatigue | Pneumonitis (inflammation of the lungs) |
| Decreased appetite | Hepatitis (inflammation of the liver) |
| Nausea | Colitis (inflammation of the colon) |
| Cough | Endocrinopathies (thyroid disorders, adrenal insufficiency, type 1 diabetes) |
| Dyspnea (shortness of breath) | Nephritis (inflammation of the kidneys) |
| Musculoskeletal pain | Infusion-related reactions |
Tecentriq Dosage Guide
| Condition | Starting Dose | Maintenance Dose | Administration Notes |
|---|---|---|---|
| Non-Small Cell Lung Cancer (NSCLC) | 840 mg | 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1200 mg every 4 weeks | Administered as an intravenous infusion over 60 minutes. |
| Urothelial Carcinoma (Bladder Cancer) | 840 mg | 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1200 mg every 4 weeks | Administered as an intravenous infusion over 60 minutes. |
| Triple-Negative Breast Cancer (TNBC) | 840 mg | 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1200 mg every 4 weeks | Administered as an intravenous infusion over 60 minutes. |
Tecentriq Price With And Without Insurance
| Purchase Context | Estimated Price |
|---|---|
| With Insurance | $300 |
| Without Insurance (U.S.) | $11,000 |
| From Canada | $10,672 |
